文献速递关节外科

膝神经阻滞加入收肌管阻滞与IPACK对初次全膝关节置换术围手术期结局的关联

What Is the Association Between Adding Genicular Nerve Block to Adductor Canal Block and Infiltration Between the Popliteal Artery and Capsule of the Knee and Perioperative Outcomes After Primary TKA?
PubMed 文献 · Clin Orthop Relat Res · 2026-04-17

这项回顾性倾向评分匹配队列研究纳入2021年1月至2024年12月接受初次全膝关节置换术的患者,比较在收肌管阻滞(ACB)加腘动脉与后关节囊间浸润(IPACK)基础上加用膝神经阻滞是否改善住院期间和麻醉后监护室(PACU)疼痛、物理治疗(PT)达标时间及90天内阿片类药物续配率。结果显示,加用膝神经阻滞在住院和门诊全膝关节置换术中均未带来临床有意义的疼痛或阿片消耗改善,也不缩短PT达标时间或降低90天续配率。

要点

  • 在ACB/IPACK基础上加用膝神经阻滞未显著改善住院期间疼痛评分或阿片消耗。
  • 加用膝神经阻滞未缩短住院或门诊全膝关节置换术后的PT达标时间。
  • 加用膝神经阻滞未降低术后90天内阿片类药物续配发生率。

核心结论

  • 在综合多模式镇痛方案下,加用膝神经阻滞对住院和门诊全膝关节置换术患者未显示临床有意义的获益,不推荐常规加用。

研究设计与样本

  • 回顾性倾向评分匹配队列研究,纳入2021年1月至2024年12月在高流量学术机构接受初次择期单侧全膝关节置换术的原发性骨关节炎成人患者。

主要发现

  • 住院期间最高疼痛和中位疼痛在干预组与对照组间无差异,门诊设置中亦无差异。
  • 住院设置中阿片消耗中位数(IQR)为53(30-82)vs 48(25-75)口服吗啡毫克当量(OME),p<0.001,但未达临床重要差异阈值。
  • 住院设置中PT达标时间中位数(IQR)为21小时(18-25)vs 22小时(19-41),p<0.001,门诊设置为13小时(4-16)vs 14小时(4-16),p=0.001,均无临床重要差异。
  • 术后90天内阿片类药物续配发生率在两组间无差异。

关键数值与推荐

  • 疼痛数字评分量表(NRS)差异≥2分或阿片消耗差异≥10 OME被视为临床重要。
  • 住院设置中PT达标时间中位差异4小时被视为临床重要,门诊设置中两组PT达标时间中位数<12小时且统计学显著被视为临床重要。

临床怎么用

  • 在已采用ACB/IPACK综合多模式镇痛的全膝关节置换术患者中,不应常规加用膝神经阻滞。
  • 对于可能获益的特定亚群,需未来证据进一步识别。

局限性

  • 回顾性研究设计,存在未测量混杂可能。
  • 证据等级为III级,治疗性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited evidence exists on the functional and analgesic efficacy of adding a genicular nerve block to an adductor canal block (ACB) plus infiltration between the popliteal artery and posterior knee capsule (IPACK) for TKA. Filling this knowledge gap would be important because if this approach were to be effective, patients could benefit from an additional opioid-free, motor-sparing analgesic modality. QUESTIONS/PURPOSES: (1) Is the addition of a genicular nerve block to an ACB/IPACK associated with better pain management during hospitalization? (2) Is the addition of a genicular nerve block to an ACB/IPACK associated with better pain management in the postanesthesia care unit (PACU)? (3) Is the addition of a genicular nerve block to an ACB/IPACK associated with earlier time to physical therapy (PT) clearance? (4) Is the addition of a genicular nerve block to an ACB/IPACK associated with lower incidence of opioid refills within 90 days postoperatively? METHODS: This was a retrospective, propensity score-matched cohort study including patients undergoing TKA from January 2021 to December 2024 at a high-volume academic institution specializing in inpatient and outpatient arthroplasty. All adults undergoing primary elective unilateral TKA for primary osteoarthritis with administration of an ACB/IPACK, with or without a genicular nerve block, were assessed for eligibility (n = 20,648). After excluding patients with American Society of Anesthesiologists physical status of > III; patients receiving general anesthesia, additional peripheral nerve blocks, or acupuncture; and patients discharged to a facility, a total of 10,156 patients undergoing inpatient TKA and 2814 patients undergoing outpatient TKA were considered eligible for propensity score matching. After a 1:1 propensity score match on baseline demographic characteristics, psychosocial factors, active opioid prior to admission, perioperative and anesthesia details, and first PT visit pass or fail, 2803 and 1102 patients from each group were analyzed for inpatient and outpatient TKAs. The median (IQR) age was 71 years (64 to 76) for inpatient TKAs and 65 years (60 to 71) for outpatient TKAs; 64% and 48% were female, respectively, and no differences among groups within the same setting were observed after matching. Aside for the comparison of interest, the same standardized perioperative pain management protocol was followed for all patients. For our first aim and second aim, we evaluated median and highest pain scores and opioid consumption. For our third aim, we assessed PT clearance, and for our fourth aim, we assessed incidence of opioid refills within 90 days. A difference in pain of ≥ 2 on the numeric rating scale (NRS) and a difference in opioid consumption of ≥ 10 oral morphine milligram equivalents (OMEs) were considered clinically meaningful. For the inpatient setting, a 4-hour median difference in time to PT clearance was considered clinically meaningful, and for the outpatient setting, any statistically significant difference with a median time to PT clearance of < 12 hours for either group was considered clinically meaningful. RESULTS: During hospitalization, we found no difference between the intervention and control group in terms of highest pain and median pain. In terms of total opioid consumption, we found no clinically important difference between the intervention group and control group (median [IQR] NRS score 55 [30 to 82] versus 52 [30 to 80]; p = 0.001) in the inpatient setting and no difference in the outpatient setting. In the PACU, we found no difference in terms of highest pain and median pain in the inpatient setting and no clinically important difference for highest pain (median [IQR] NRS score 7 [5 to 8] versus 7 [6 to 8]; p = 0.03) in the outpatient setting. In the inpatient setting, no clinically important difference was observed between the intervention and control group for opioid consumption (median [IQR] OMEs 53 [30 to 82] versus 48 [25 to 75]; p < 0.001); no difference was observed in the outpatient setting. We found no clinically meaningful difference between the intervention group and control group in terms of time to PT clearance in the inpatient setting (median [IQR] 21 hours [18 to 25] versus 22 hours [19 to 41]; p < 0.001) and the outpatient setting (median [IQR] 13 hours [4 to 16] versus 14 hours [4 to 16]; p = 0.001). We found no difference in terms of incidence of opioid refills within 90 days. CONCLUSION: The associations we found do not justify the addition of a genicular nerve block in patients undergoing inpatient and outpatient TKA with a comprehensive multimodal analgesia protocol given the modest, at best, effect size observed, its potential financial cost and time cost, and risk for adverse events. Our study suggested that there are subpopulations in the general TKA population that could potentially benefit from the addition of genicular nerve block, but until future evidence identifies these subpopulations, our data suggest that the addition of a genicular nerve block was not associated with any clinically meaningful benefit in the general TKA population. LEVEL OF EVIDENCE: Level III, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Giannakis P, Yu S, Illescas A, et al. What Is the Association Between Adding Genicular Nerve Block to Adductor Canal Block and Infiltration Between the Popliteal Artery and Capsule of the Knee and Perioperative Outcomes After Primary TKA? Clin Orthop Relat Res. 2026. PMID: 41996683. doi:10.1097/CORR.0000000000003938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。